search
Back to results

Prevention of Infections in Cardiac Surgery (PICS)

Primary Purpose

Thoracic Surgery, Antibiotic Prophylaxis

Status
Active
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
Cefazolin
Vancomycin
Sponsored by
Hamilton Health Sciences Corporation
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Thoracic Surgery

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • All adult patients (≥18 years of age) undergoing open-heart surgery (sternotomy, including minimally-invasive surgical techniques).

Exclusion Criteria:

  • Patients on antibiotics at the time of surgery.
  • Previous enrollment in this trial.
  • Known MRSA carriers. Beta-lactam allergy (IgE-mediated) precluding the use of cefazolin
  • Participant in another study that may interfere with this trial.

Sites / Locations

  • Hamilton Health Sciences
  • St. Michael's Hospital
  • Jewish Hospital
  • University of Sherbrook

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Experimental

Experimental

Experimental

Arm Label

Cefazolin monotherapy, short course

Cefazolin monotherapy, long course

Combination therapy, short course

Combination therapy, long course

Arm Description

One pre-op dose of cefazolin 30-60 minutes prior to surgery followed by a second dose either four hours after the first dose or upon wound closure (whatever comes first) will be administered

One pre-op dose of cefazolin 30-60 minutes prior to surgery followed by a second dose either four hours after the first dose or upon wound closure (whatever comes first) will be administered followed by additional five doses every eight hours postoperatively (last dose 44 hours after the first dose).

One pre-op dose of cefazolin 30-60 minutes prior to surgery followed by a second dose either four hours after the first dose or upon wound closure (whatever comes first) will be administered. In addition, one dose of vancomycin 60-90min pre-op will be administered.

One pre-op dose of cefazolin 30-60 minutes prior to surgery followed by a second dose either four hours after the first dose or upon wound closure (whatever comes first) will be administered followed by additional five doses every eight hours postoperatively (last dose 44 hours after the first dose). In addition, one dose of vancomycin 60-90min pre-op will be administered followed by 3 post-op doses every 12 hours (last dose 36 hours after first dose)

Outcomes

Primary Outcome Measures

Proportion of patients receiving antibiotics according to study protocol
Co-Primary outcome of pilot study
Proportion of patients with complete follow-up, i.e. up to 90 days or death; goal >95%
Co-Primary outcome of pilot study
Agreement of blinded outcome assessment based on information from the case report form
Co-Primary outcome of pilot study

Secondary Outcome Measures

Deep incisional and organ/space sternal surgical site infection (NHSN/CDC)
Primary outcome of eventual full trial
All types of sternal surgical site infection (superficial, deep, organ; NHSN/CDC)
Secondary outcome of eventual full trial
Mortality
Secondary outcome of eventual full trial
Clostridium difficile infection
Secondary outcome of eventual full trial

Full Information

First Posted
November 4, 2014
Last Updated
September 20, 2023
Sponsor
Hamilton Health Sciences Corporation
Collaborators
The Physicians' Services Incorporated Foundation
search

1. Study Identification

Unique Protocol Identification Number
NCT02285140
Brief Title
Prevention of Infections in Cardiac Surgery
Acronym
PICS
Official Title
Prevention of Infections in Cardiac Surgery: a Cluster-randomized Factorial Cross-over Trial
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
April 2015 (undefined)
Primary Completion Date
August 7, 2026 (Anticipated)
Study Completion Date
November 7, 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Hamilton Health Sciences Corporation
Collaborators
The Physicians' Services Incorporated Foundation

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
There is clinical equipoise about the question of whether antibiotic prophylaxis should be given for a short period or an extended period of time as reflected by inconsistencies in major guidelines, current practices at Canadian centers, and as concluded in the three systematic reviews. There also is clinical equipoise on whether the addition of vancomycin to routine cefazolin prophylaxis can further reduce s-SSI rates. A short duration of combined antimicrobial prophylaxis can reduce side effects of exposure to antimicrobials such as infections with C. difficile or emergence of resistance, but may also reduce the incidence of s-SSIs. The objective of the eventual full scale study is to determine whether adding vancomycin to cefazolin can reduce SSIs as well as whether short-term prophylaxis is as effective as long-term prophylaxis. The rationale to conduct the proposed pilot study is to assess the feasibility to conduct this factorial cluster randomized cross-over trial, the adherence to the study protocol at each pilot site, the length of time to fill out the case report forms, and to get reliable estimates of event rates for sample size calculation for the main study

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Thoracic Surgery, Antibiotic Prophylaxis

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Factorial Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
3000 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Cefazolin monotherapy, short course
Arm Type
Experimental
Arm Description
One pre-op dose of cefazolin 30-60 minutes prior to surgery followed by a second dose either four hours after the first dose or upon wound closure (whatever comes first) will be administered
Arm Title
Cefazolin monotherapy, long course
Arm Type
Experimental
Arm Description
One pre-op dose of cefazolin 30-60 minutes prior to surgery followed by a second dose either four hours after the first dose or upon wound closure (whatever comes first) will be administered followed by additional five doses every eight hours postoperatively (last dose 44 hours after the first dose).
Arm Title
Combination therapy, short course
Arm Type
Experimental
Arm Description
One pre-op dose of cefazolin 30-60 minutes prior to surgery followed by a second dose either four hours after the first dose or upon wound closure (whatever comes first) will be administered. In addition, one dose of vancomycin 60-90min pre-op will be administered.
Arm Title
Combination therapy, long course
Arm Type
Experimental
Arm Description
One pre-op dose of cefazolin 30-60 minutes prior to surgery followed by a second dose either four hours after the first dose or upon wound closure (whatever comes first) will be administered followed by additional five doses every eight hours postoperatively (last dose 44 hours after the first dose). In addition, one dose of vancomycin 60-90min pre-op will be administered followed by 3 post-op doses every 12 hours (last dose 36 hours after first dose)
Intervention Type
Drug
Intervention Name(s)
Cefazolin
Intervention Description
administration as outlined
Intervention Type
Drug
Intervention Name(s)
Vancomycin
Intervention Description
administration as outlined
Primary Outcome Measure Information:
Title
Proportion of patients receiving antibiotics according to study protocol
Description
Co-Primary outcome of pilot study
Time Frame
3 months post-surgery
Title
Proportion of patients with complete follow-up, i.e. up to 90 days or death; goal >95%
Description
Co-Primary outcome of pilot study
Time Frame
3 months post-surgery
Title
Agreement of blinded outcome assessment based on information from the case report form
Description
Co-Primary outcome of pilot study
Time Frame
3 months post-surgery
Secondary Outcome Measure Information:
Title
Deep incisional and organ/space sternal surgical site infection (NHSN/CDC)
Description
Primary outcome of eventual full trial
Time Frame
3 months post-surgery
Title
All types of sternal surgical site infection (superficial, deep, organ; NHSN/CDC)
Description
Secondary outcome of eventual full trial
Time Frame
3 months post-surgery
Title
Mortality
Description
Secondary outcome of eventual full trial
Time Frame
3 months post-surgery
Title
Clostridium difficile infection
Description
Secondary outcome of eventual full trial
Time Frame
3 months post-surgery

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: All adult patients (≥18 years of age) undergoing open-heart surgery (sternotomy, including minimally-invasive surgical techniques). Exclusion Criteria: Patients on antibiotics at the time of surgery. Previous enrollment in this trial. Known MRSA carriers. Beta-lactam allergy (IgE-mediated) precluding the use of cefazolin Participant in another study that may interfere with this trial.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Dominik Mertz, MD, MSc
Organizational Affiliation
Hamilton Health Sciences Corporation
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hamilton Health Sciences
City
Hamilton
State/Province
Ontario
ZIP/Postal Code
L8L 2X2
Country
Canada
Facility Name
St. Michael's Hospital
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M5B1W8
Country
Canada
Facility Name
Jewish Hospital
City
Montréal
State/Province
Quebec
ZIP/Postal Code
H3T 1E2
Country
Canada
Facility Name
University of Sherbrook
City
Sherbrook
State/Province
Quebec
ZIP/Postal Code
J1H 5N4
Country
Canada

12. IPD Sharing Statement

Citations:
PubMed Identifier
30558680
Citation
van Oostveen RB, Romero-Palacios A, Whitlock R, Lee SF, Connolly S, Carignan A, Mazer CD, Loeb M, Mertz D. Prevention of Infections in Cardiac Surgery study (PICS): study protocol for a pragmatic cluster-randomized factorial crossover pilot trial. Trials. 2018 Dec 17;19(1):688. doi: 10.1186/s13063-018-3080-y. Erratum In: Trials. 2019 Oct 16;20(1):595.
Results Reference
derived

Learn more about this trial

Prevention of Infections in Cardiac Surgery

We'll reach out to this number within 24 hrs